S&P 500   5,096.27
DOW   38,996.39
QQQ   439.00
Pure Storage, Hormel Foods rise; WW International, First Advantage fall, Thursday, 2/29/2024
This is the #1 Stock to Buy for the AI Tidal Wave (Ad)
How major US stock indexes fared Thursday, 2/29/2024
Average long-term US mortgage rises to 6.94% after marking fourth-straight weekly increase
Critical asset just had biggest fall on record (Ad)
Best Buy reports lower 4Q sales and profits as shoppers remain cautious
Grads From This Midwestern School Are More Likely to Start a Billion Dollar Company Than Founders Who Went To Stanford, Harvard, or MIT: Study
This is the #1 Stock to Buy for the AI Tidal Wave (Ad)
It's Leap Day, and You're Probably Working — Here's How 'February 29' Affects Your Paycheck
From Hometown Hero to Franchise Partner — 3 Celebrities Collaborating With Their Hometown Brands
S&P 500   5,096.27
DOW   38,996.39
QQQ   439.00
Pure Storage, Hormel Foods rise; WW International, First Advantage fall, Thursday, 2/29/2024
This is the #1 Stock to Buy for the AI Tidal Wave (Ad)
How major US stock indexes fared Thursday, 2/29/2024
Average long-term US mortgage rises to 6.94% after marking fourth-straight weekly increase
Critical asset just had biggest fall on record (Ad)
Best Buy reports lower 4Q sales and profits as shoppers remain cautious
Grads From This Midwestern School Are More Likely to Start a Billion Dollar Company Than Founders Who Went To Stanford, Harvard, or MIT: Study
This is the #1 Stock to Buy for the AI Tidal Wave (Ad)
It's Leap Day, and You're Probably Working — Here's How 'February 29' Affects Your Paycheck
From Hometown Hero to Franchise Partner — 3 Celebrities Collaborating With Their Hometown Brands
S&P 500   5,096.27
DOW   38,996.39
QQQ   439.00
Pure Storage, Hormel Foods rise; WW International, First Advantage fall, Thursday, 2/29/2024
This is the #1 Stock to Buy for the AI Tidal Wave (Ad)
How major US stock indexes fared Thursday, 2/29/2024
Average long-term US mortgage rises to 6.94% after marking fourth-straight weekly increase
Critical asset just had biggest fall on record (Ad)
Best Buy reports lower 4Q sales and profits as shoppers remain cautious
Grads From This Midwestern School Are More Likely to Start a Billion Dollar Company Than Founders Who Went To Stanford, Harvard, or MIT: Study
This is the #1 Stock to Buy for the AI Tidal Wave (Ad)
It's Leap Day, and You're Probably Working — Here's How 'February 29' Affects Your Paycheck
From Hometown Hero to Franchise Partner — 3 Celebrities Collaborating With Their Hometown Brands
S&P 500   5,096.27
DOW   38,996.39
QQQ   439.00
Pure Storage, Hormel Foods rise; WW International, First Advantage fall, Thursday, 2/29/2024
This is the #1 Stock to Buy for the AI Tidal Wave (Ad)
How major US stock indexes fared Thursday, 2/29/2024
Average long-term US mortgage rises to 6.94% after marking fourth-straight weekly increase
Critical asset just had biggest fall on record (Ad)
Best Buy reports lower 4Q sales and profits as shoppers remain cautious
Grads From This Midwestern School Are More Likely to Start a Billion Dollar Company Than Founders Who Went To Stanford, Harvard, or MIT: Study
This is the #1 Stock to Buy for the AI Tidal Wave (Ad)
It's Leap Day, and You're Probably Working — Here's How 'February 29' Affects Your Paycheck
From Hometown Hero to Franchise Partner — 3 Celebrities Collaborating With Their Hometown Brands

Navidea Biopharmaceuticals (NAVB) Competitors

$0.04
0.00 (0.00%)
(As of 02/29/2024 ET)

NAVB vs. MYMD, VRAX, TRIB, ARTL, PBM, GCTK, AVGR, KZIA, LSDI, and LUCY

Should you be buying Navidea Biopharmaceuticals stock or one of its competitors? The main competitors of Navidea Biopharmaceuticals include MyMD Pharmaceuticals (MYMD), Virax Biolabs Group (VRAX), Trinity Biotech (TRIB), Artelo Biosciences (ARTL), Psyence Biomedical (PBM), GlucoTrack (GCTK), Avinger (AVGR), Kazia Therapeutics (KZIA), Lucy Scientific Discovery (LSDI), and Innovative Eyewear (LUCY). These companies are all part of the "medical" sector.

Navidea Biopharmaceuticals vs.

MyMD Pharmaceuticals (NASDAQ:MYMD) and Navidea Biopharmaceuticals (NYSE:NAVB) are both small-cap medical companies, but which is the better business? We will contrast the two businesses based on the strength of their community ranking, analyst recommendations, dividends, profitability, risk, earnings, valuation, institutional ownership and media sentiment.

MyMD Pharmaceuticals has a beta of 2.38, suggesting that its stock price is 138% more volatile than the S&P 500. Comparatively, Navidea Biopharmaceuticals has a beta of 1.15, suggesting that its stock price is 15% more volatile than the S&P 500.

9.6% of MyMD Pharmaceuticals shares are owned by institutional investors. Comparatively, 15.8% of Navidea Biopharmaceuticals shares are owned by institutional investors. 2.6% of MyMD Pharmaceuticals shares are owned by company insiders. Comparatively, 43.7% of Navidea Biopharmaceuticals shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock is poised for long-term growth.

MyMD Pharmaceuticals and Navidea Biopharmaceuticals both received 0 outperform votes by MarketBeat users.

CompanyUnderperformOutperform
MyMD PharmaceuticalsN/AN/A
Navidea BiopharmaceuticalsOutperform Votes
No Votes
Underperform Votes
31
100.00%

Navidea Biopharmaceuticals has higher revenue and earnings than MyMD Pharmaceuticals. Navidea Biopharmaceuticals is trading at a lower price-to-earnings ratio than MyMD Pharmaceuticals, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
MyMD PharmaceuticalsN/AN/A-$15.20M-$5.41-0.63
Navidea Biopharmaceuticals$70K60.41-$15.18M-$0.06-0.70

In the previous week, MyMD Pharmaceuticals and MyMD Pharmaceuticals both had 2 articles in the media. Navidea Biopharmaceuticals' average media sentiment score of 1.27 beat MyMD Pharmaceuticals' score of 0.23 indicating that MyMD Pharmaceuticals is being referred to more favorably in the media.

Company Overall Sentiment
MyMD Pharmaceuticals Positive
Navidea Biopharmaceuticals Neutral

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
MyMD Pharmaceuticals
0 Sell rating(s)
0 Hold rating(s)
0 Buy rating(s)
0 Strong Buy rating(s)
N/A
Navidea Biopharmaceuticals
0 Sell rating(s)
0 Hold rating(s)
0 Buy rating(s)
0 Strong Buy rating(s)
N/A

MyMD Pharmaceuticals' return on equity of 0.00% beat Navidea Biopharmaceuticals' return on equity.

Company Net Margins Return on Equity Return on Assets
MyMD PharmaceuticalsN/A -109.02% -62.65%
Navidea Biopharmaceuticals N/A N/A -166.65%

Summary

Navidea Biopharmaceuticals beats MyMD Pharmaceuticals on 6 of the 10 factors compared between the two stocks.


Get Navidea Biopharmaceuticals News Delivered to You Automatically

Sign up to receive the latest news and ratings for NAVB and its competitors with MarketBeat's FREE daily newsletter.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding NAVB and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
Skip Chart

Media Sentiment Over Time

This chart shows the average media sentiment of NYSE and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Skip Chart

NAVB vs. The Competition

MetricNavidea BiopharmaceuticalsDiagnostic substances IndustryMedical SectorNYSE Exchange
Market Cap$4.23M$2.91B$4.91B$17.48B
Dividend YieldN/A0.82%2.90%3.57%
P/E Ratio-0.7051.11256.5225.87
Price / Sales60.41167.413,327.607.42
Price / CashN/A5,004.4596.1816.89
Price / Book-0.174.074.455.75
Net Income-$15.18M$30.34M$114.26M$863.03M
7 Day PerformanceN/A-0.64%4.23%0.97%
1 Month PerformanceN/A-0.47%8.77%1.92%
1 Year PerformanceN/A-32.09%12.18%105.16%

Navidea Biopharmaceuticals Competitors List

CompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)
MYMD
MyMD Pharmaceuticals
0 of 5 stars
$3.51
+5.7%
N/A-94.0%$5.97MN/A-0.6510Short Interest ↓
VRAX
Virax Biolabs Group
0 of 5 stars
$0.89
-7.3%
N/A-85.9%$1.38M$10,000.000.0011Short Interest ↓
News Coverage
Gap Down
TRIB
Trinity Biotech
0.7579 of 5 stars
$0.45
-6.3%
N/A-58.7%$17.07M$74.78M-0.60398Analyst Report
Stock Split
Short Interest ↓
ARTL
Artelo Biosciences
3.2771 of 5 stars
$1.67
+3.1%
$32.50
+1,846.1%
-46.6%$4.78MN/A-0.505Short Interest ↓
High Trading Volume
PBM
Psyence Biomedical
0 of 5 stars
$0.54
-5.2%
N/AN/A$4.78MN/A0.00N/AShort Interest ↑
Gap Up
GCTK
GlucoTrack
0 of 5 stars
$0.23
flat
N/A-75.1%$4.83MN/A-0.643Short Interest ↑
Gap Up
AVGR
Avinger
1.9869 of 5 stars
$3.56
-16.2%
$5.00
+40.4%
-77.4%$4.88M$8.27M-0.1171Analyst Report
Short Interest ↑
News Coverage
Gap Down
High Trading Volume
KZIA
Kazia Therapeutics
3.4241 of 5 stars
$0.30
-6.3%
$2.00
+567.8%
-72.3%$4.89M$20,000.000.002,021Short Interest ↓
Gap Down
LSDI
Lucy Scientific Discovery
0 of 5 stars
$0.26
+12.8%
N/A-91.7%$4.67M$10,000.00-0.382Stock Split
Short Interest ↓
Gap Down
LUCY
Innovative Eyewear
2.9895 of 5 stars
$0.39
flat
$1.75
+354.3%
-78.4%$4.98M$660,000.000.009Upcoming Earnings
Short Interest ↓
Positive News

Related Companies and Tools

This page (NYSE:NAVB) was last updated on 3/1/2024 by MarketBeat.com Staff